Revolution Medicines, Inc. Stock Price, News & Analysis

Revolution Medicines, Inc. (Nasdaq: RVMD) reported its financial results for Q3 2021, highlighting significant advancements in its RAS(ON) Inhibitor pipeline. The company continues to progress candidates RMC-6291 (KRASG12C) and RMC-6236 (RASMULTI), with plans to select another development candidate by year-end. Preclinical data show RMC-6291's superior anti-tumor activity compared to adagrasib. However, total revenue fell to $1.1 million from $12.7 million YoY, influenced by an $8.5 million non-cash adjustment. The net loss increased to $52.9 million, with a full-year guidance net loss projected between $170 million and $190 million.

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company, will participate in the Stifel 2021 Virtual Healthcare Conference from November 15-17, 2021. CEO Mark A. Goldsmith will engage in a fireside chat on November 15 at 2:40 p.m. Eastern. The company focuses on developing drugs that target RAS-addicted cancers through innovative drug discovery capabilities. Its R&D pipeline features RAS(ON) Inhibitors like RMC-6291 and RMC-6236, along with various RAS Companion Inhibitors, aimed at enhancing cancer treatment strategies.

Revolution Medicines, Inc. (RVMD) will announce its third quarter 2021 financial results on November 10, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET, led by senior management discussing financials and corporate developments. The company focuses on precision oncology, developing targeted therapies for RAS-addicted cancers. Their R&D pipeline includes RAS(ON) Inhibitors like RMC-6291 and RMC-6236, and RAS Companion Inhibitors such as RMC-4630. The live webcast and archives can be accessed on their website.

Revolution Medicines announced an invited oral presentation at the upcoming AACR-NCI-EORTC Virtual International Conference, showcasing preclinical data from its RAS(ON) inhibitor programs. Scheduled for October 9, 2021, the session will feature Steve Kelsey, M.D., presenting on the discovery and development of RAS(ON) inhibitors targeting various oncogenic RAS variants. This highlights the company's ongoing efforts in developing targeted therapies for RAS-addicted cancers.

Revolution Medicines (Nasdaq: RVMD) announced its participation in the 3rd Annual RAS-Targeted Drug Development Summit from September 21-23, 2021. Key presentations include:

• Targeting KRASG12C(ON) by Bob Nichols, Ph.D. on September 22 at 11:55 a.m. Eastern.
• Combination Strategies for RAS-Addicted Cancers by Jan Smith, Ph.D. on September 22 at 2:00 p.m. Eastern.
• Panel discussion moderated by Steve Kelsey, M.D. on September 23 at 4:15 p.m. Eastern.

The Company focuses on developing targeted therapies for RAS-addicted cancers.

Revolution Medicines, a clinical-stage oncology company (Nasdaq: RVMD), announced that CEO Mark A. Goldsmith will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. Eastern Time. The conference runs from September 13-15, 2021, in a virtual format with a live webcast accessible on the company’s website. Revolution Medicines specializes in developing targeted therapies for RAS-addicted cancers, with its R&D pipeline including RAS(ON) Inhibitors and RAS Companion Inhibitors.

Revolution Medicines, focusing on RAS-addicted cancer treatments, reported Q2 2021 financial results, highlighting a decrease in revenue to $8.7 million, down from $10 million in Q2 2020. They reported a net loss of $44.3 million compared to $27.2 million last year. The company is advancing its RAS(ON) Inhibitor portfolio, deprioritizing indirect combinations in favor of direct RAS inhibitor combinations. A strategic collaboration with Amgen for a global Phase 2 study of RMC-4630 with Lumakras™ was announced. Financial guidance estimates a full year net loss between $170-$190 million, including around $20 million in stock-based compensation.

Revolution Medicines (Nasdaq: RVMD) will report its Q2 2021 financial results on August 11, 2021, after market close. A conference call and webcast are scheduled for 4:30 p.m. Eastern Time, where senior management will discuss the results and recent company developments. Revolution Medicines focuses on developing targeted therapies for RAS-addicted cancers and has a diverse R&D pipeline including RAS(ON) and RAS Companion Inhibitors such as RMC-6291 and RMC-4630. The live webcast will be accessible via the company’s website, followed by an archived version for at least 14 days.

Revolution Medicines has announced the publication of a study in Nature Chemical Biology showcasing the anti-tumor effects of its first-in-class RMC-5552, a bi-steric mTORC1-selective inhibitor. The study highlights RMC-5552's potential to selectively inhibit mTORC1, preserving the tumor suppressor 4EBP1, which may increase anti-tumor efficacy, especially in RAS-addicted cancers. The company has initiated a Phase 1/1b clinical trial to evaluate RMC-5552's safety and effectiveness against advanced solid tumors.